A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

9284 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-04-15

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Non-interventional, Single-country study based on existing data from medical records of COPD patients treated with LAMA or fixed dose combination of ICS/LABA

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tiotropium in Patients With Tuberculosis (TB) Destroyed Lung

NCT01365702

Lung Disease, Obstructive Tuberculosis

UNKNOWN

Non-interventional Study Related to Fixed LAMA/LABA/ICS Triple Therapy

NCT04355546

COPD

COMPLETED

Effect of Tiotropium on Airway Remodeling in Patients With Early Stage COPD Accessed by Optical Coherence Tomography

NCT03842839

Airway Remodeling

UNKNOWN NA

Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]

NCT03265145

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE4

Tiotropium 18ug Inhalation Capsule Using a Handihaler® Among Korean COPD Patients

NCT00620516

Pulmonary Disease, Chronic Obstructive

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease, Chronic Obstructive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LAMA

Chronic obstructive pulmonary disease (COPD) patients who were prescribed long-acting muscarinic antagonists (LAMA) monotherapy between 01 January 2005 and 30 April 2015.

Long-acting Muscarinic Antagonists (LAMA)

Intervention Type DRUG

drug

ICS/LABA

Chronic obstructive pulmonary disease (COPD) patients who were prescribed a fixed-dose combination (FDC) of inhaled corticosteroid (ICS)/long-acting beta agonists (LABA) between 01 January 2005 and 30 April 2015.

Inhaled corticosteroid (ICS)/Long-acting Beta Agonists (LABA)

Intervention Type DRUG

drug

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Long-acting Muscarinic Antagonists (LAMA)

drug

Intervention Type DRUG

Inhaled corticosteroid (ICS)/Long-acting Beta Agonists (LABA)

drug

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with COPD \[based on ICD-10 code(J43.x-44.x except J430), as the primary or within the fourth secondary diagnosis and initiated LAMA or ICS/LABA more than twice a year from Jan 1, 2005 to Apr 30 2016\].
* Age \>55 years old

Exclusion Criteria

* Prescription history with any long acting bronchodilator for maintenance therapy (the patient should be inhaler naïve)
* Prescription history with ipratropium bromide
* Prescription history with Leukotriene receptor antagonist(LTRA) or ICS
* Patients with lung cancer, IPF, ILD or lung transplantation at the time of COPD diagnosis

Minimum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No